Up‐front autologous hematopoietic stem cell transplantation after first complete remission improved prognosis of advanced extra‐nodal NKT cell lymphoma: A multicenter real‐world study in China. (28th March 2023)

• Record Type: Journal Article
• Authors: Gao, Honghao; Lin, Ningjing; Gu, Zhenyang; Zhao, Shihua; Wang, Xiaopei; Yuan, Shunzong; Song, Yuqin; Zhu, Jun; Huang, Wenrong; Liu, Weiping; Gao, Chunji
• Is Part Of: European journal of haematology. Volume 110:Number 6(2023)
• Page Start: 680
• Page End: 687
• Publication Date: 2023-03-28
• Subjects: advanced extra‐nodal NK/T‐cell lymphoma (ENKTL) -- autologous hematopoietic stem cell transplantation (ASCT) -- chemotherapy; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.13950
• Languages: English
• ISSNs: 0902-4441

Abstract

Abstract: Objectives: The advanced extra‐nodal NK/T‐cell lymphoma (ENKTL) is highly aggressive and lacks effective treatment with a poor prognosis. This study aimed to investigate the effectiveness and safety of autologous hematopoietic stem cell transplantation (ASCT) in CR1. Methods: Forty of 121 patients with advanced ENKTL from four Chinese hospitals between January 2006 to December 2021 who achieved first complete remission (CR1) and received at least 4 cycles chemotherapy, were enrolled for analysis. Twenty patients received ASCT as up‐front consolidation therapy (Group A), and 20 patients only received chemotherapy (Group B). Clinical features, treatment and follow‐up information were collected. Results: With a median follow‐up of 27 months (range, 4–188 months), the 2‐year overall survival (OS) in Group A, 61% (95% CI 37%–85%), was better than that in Group B, 26% (95% CI 2%–50%), p = .018. The 2‐year progression‐free survival (PFS) was 56% (95% CI 32%–80%) in Group A, 26% (95% CI 2%–50%) in Group B, p = .026. III–IV grade hematological toxicity was the most common adverse event. No treatment‐related deaths were observed in both groups. Conclusion: Up‐front ASCT could improve survival of advanced ENKTL patients in first complete remission, but need be confirmed by a prospective clinical trial.